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OBJECTIVE—a-Melanocyte–stimulating hormone (a-MSH) and
agouti-related peptide (AgRP) control energy homeostasis by
their opposing actions on melanocortin receptors (MC3/4R) in
the hypothalamus. We previously reported that thyroid transcrip-
tion factor-1 (TTF-1) controls feeding behavior in the hypothala-
mus. This study aims to identify the function of TTF-1 in the
transcriptional regulation of AgRP and a-MSH synthesis for the
control of feeding behavior.
RESEARCH DESIGN AND METHODS—TTF-1 activity in
AgRP and pro-opiomelanocortin (POMC) transcription was
examined using gel-shift and promoter assays and an in vivo
model of TTF-1 synthesis inhibition by intracerebroventricular
injection of an antisense (AS) oligodeoxynucleotide (ODN). Double
immunohistochemistry was performed to colocalize TTF-1 and
AgRP or a-MSH in the hypothalamic arcuate nucleus (ARC). To
determine whether TTF-1 action on food intake is mediated
through MC3/4R, we measured changes in food intake upon intra-
cerebroventricular injection of MC3/4R antagonists (SHU9119
and AgRP) into rat brain preinjected with the AS ODN.
RESULTS—TTF-1 stimulated AgRP but inhibited POMC tran-
scription by binding to the promoters of these genes. TTF-1 was
widely distributed in the hypothalamus, but we identiﬁed some
cells coexpressing TTF-1 and AgRP or a-MSH in the ARC. In
addition, intracerebroventricular administration of leptin decreased
TTF-1 expression in the hypothalamus, and AS ODN-induced
inhibition of TTF-1 expression decreased food intake and AgRP
expression but increased a-MSH expression. Anorexia induced
by the AS ODN was attenuated by the administration of MC3/4R
antagonists.
CONCLUSIONS—TTF-1 transcriptionally regulates synthesis of
AgRP and a-MSH in the ARC and affects feeding behavior via the
melanocortin pathway. Diabetes 60:710–719, 2011
T
he central nervous system plays a critical role in
maintaining energy homeostasis by regulating
both energy intake and expenditure, and the
hypothalamus is a core site that integrates the
peripheral and central signals.
Neuropeptidergic, monoaminergic, and endocannabinoid
systems are involved in the central control of appetite. A
key system for regulation of energy homeostasis includes
functionally opposing neuronal populations in the arcu-
ate nucleus (ARC) that express neuropeptide Y (NPY)
and agouti-related peptide (AgRP) to stimulate food in-
take and proopiomelanocortin (POMC) and cocaine- and
amphetamine-regulated transcript (CART) to induce an-
orexia (1).
The melanocortin (MC) signaling pathway in the hypo-
thalamus is important for energy homeostasis (2). Regula-
tion through this pathway is exerted by two opposing
neuronal components: AgRP and a-melanocyte–stimulating
hormone (a-MSH), which is produced from a POMC pre-
cursor protein. a-MSH activates target neurons expressing
MC-3 (MC3R) and MC-4 (MC4R) receptors, increases en-
ergy expenditure, and decreases food intake, whereas AgRP
counteracts the anorexic effect of a-MSH as an MC3/4R
antagonist (2). Thus a characteristic obese phenotype, typ-
iﬁed with hyperphagia, increased linear growth, and meta-
bolic defects, appears in mice bearing POMC- and MC4R-null
mutations and in transgenic mice overexpressing AgRP
(3–5). Likewise, humans with an MC4R mutation also show
severe early-onset obesity (6). Together, these studies sug-
gest the importance of the central MC signaling pathway in
the regulation of food intake and energy expenditure.
Thyroid transcription factor-1 (TTF-1), also known as
Nkx2.1 and T/ebp, is a transcription factor that was ﬁrst
identiﬁed in the thyroid gland (7). TTF-1 is also expressed
in discrete regions of the postnatal rat brain, where it
regulates the synthesis of neuropeptides and proteins in-
volved in the control of body homeostasis (8–13). The ARC
is one of the hypothalamic nuclei that exhibits strong TTF-
1 expression in the postnatal rat brain (9,14). We have
previously reported that TTF-1 synthesis blockade in the
hypothalamus results in decreased food intake and body
weight (14). However, the mechanism by which TTF-1
regulates food intake is largely unknown. Here we show
that TTF-1 plays a critical role in the control of the MC
pathway by regulating AgRP and POMC gene transcription
in the ARC.
RESEARCH DESIGN AND METHODS
Cell culture and promoter assays. Rat neuroblastoma B35 cells and mouse
pituitary adenoma AtT-20 cells were grown in Dulbecco’s modiﬁed Eagle’s
medium supplemented with high glucose (4.5 g/L) and 10% fetal bovine serum
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ORIGINAL ARTICLEat 37°C in a humidiﬁed atmosphere with 5% CO2. Cells were transiently
transfected with AgRP (AGRP-pGL3 in B35 cells) or POMC (POMC-pGL3 in
AtT-20 cells) promoter-luciferase reporter constructs and various concen-
trations (100–500 ng/well) of the TTF-1 expression vector TTF-1-pcDNA.
Lipofectamine/PLUS (Invitrogen Life Technologies, Gaithersburg, MD) was
used to improve the transfection efﬁcacy, which was normalized by cotrans-
fecting the b-galactosidase reporter plasmid pCMV-b-gal (Clontech, Palo Alto,
CA) at 20 ng/well. The transfection efﬁciency of this method, as measured by
the green ﬂuorescent protein (GFP) expression ratio after transfecting GFP-
conjugated TTF-1, was ;70% (data not shown). Cells were harvested 24 h after
transfection for luciferase and b-galactosidase assays.
DNA constructs. The human AgRP promoter (15) (NCBI GenBank database
accession no. AF314194) inserted into a luciferase reporter plasmid (16) was
provided by Dr. M.S. Kim (College of Medicine, University of Ulsan, Seoul,
Korea). The proximal promoter of the rat POMC gene (2706 to +3 bp) was
cloned by PCR from rat genomic DNA, based on sequence information (17)
(NCBI GenBank database accession no. X03171; sense primer, 59-GCT TCC
ACT TCC CTC CAC AGA-39; antisense primer, 59-TTT GGT CCC TGT CAC
TCT TCT-39), and was inserted into a pGL-3 basic vector (Promega, Madison,
WI). Mutant AgRP and POMC promoter constructs carrying deletions of the
core TTF-1 binding motifs were generated using a QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). To inhibit endogenous TTF-1
synthesis in B35 and AtT-20 cells, cells were transfected with the pLKO.1-Puro
vector (Sigma-Aldrich) carrying a small hairpin RNA (shRNA) that targeted
the 30th to 50th nucleotides (59-GTT CTC AGT GTC TGA CAT CTT-39)i nt h e
TTF-1 mRNA sequence (18).
Electrophoretic mobility shift assay. The expression and puriﬁcation of the
TTF-1 homeodomain (TTF-1 HD) protein has been described previously (19).
Double-stranded oligodeoxynucleotide (ODN) probes, containing putative
TTF-1 core binding motifs and their ﬂanking sequences from the AgRP and
POMC promoter regions (Supplementary Figs. 1 and 2), were synthesized as
complementary pairs, end-labeled with [g-
32P]ATP in a reaction with T4 DNA
polynucleotide kinase, and puriﬁed over a NICK column (Amersham Phar-
macia). ODNs C and Cb were used as a positive and negative control, re-
spectively (20). Electrophoretic mobility shift assay (EMSA) was performed as
previously described (10,11) using the TTF-1 HD protein at 75 and 150 nmol/L
with ODNs at 5 mmol/L. To determine the binding activity of hypothalamic
nuclear extracts to probes containing TTF-1 binding domains, nuclear protein
from rat hypothalamus was prepared using a nuclear protein extraction kit
(Pierce, Rockford, IL). The binding assay was performed using 15 mg of pro-
tein and 20,000 counts per minute of probe (2133 in the AGRP promoter
and 2566 in the POMC promoter). To conﬁrm the presence of immunoreac-
tive TTF-1 in nuclear extracts, proteins were incubated with 1 ml of undiluted
TTF-1 antiserum (NeoMarkers, Fremont, CA) for 30 min at room temperature
before the binding reactions.
Animals. Two-month-old male Sprague-Dawley rats (Daehan Animal Breeding
Company, Chungwon, Korea) were used, and animal experiments were con-
ducted as required by the Regulations of the University of Ulsan for the Care
and Use of Laboratory Animals. Rats were housed in a room with a conditioned
photoperiod (12-h light/12-h dark cycle; lights on from 0600–1800 h) and
temperature (23–25°C) and allowed ad libitum access to tap water and pel-
leted rat chow.
Micropunch dissection. Rats were killed by decapitation, and brains were
rapidly frozen in 2-methylbutane on dry ice for 5 min. Brains were sectioned
(500-mm thickness) in a cryostat at 215°C and then mounted on glass slides.
Using anatomical landmarks from a rat brain atlas, the ARCs were punched
out using a micropunching set (Stoelting, Wood Dale, IL) and were kept in
microcentrifuge tubes at 280°C.
Real-time PCR. RNA was isolated from the ARC using Trizol reagent (Sigma-
Aldrich) and then reverse-transcribed and ampliﬁed by real-time PCR using the
following primer sets: AgRP sense primer, 59-TCC CAG AGT TCT CAG GTC TA -39;
AgRP antisense primer, 59-CTT GAA GAA GCG GCA GTA G -39; POMC sense
primer, 59-GCT AGG TAA CAA ACG AAT GG-39; POMC antisense primer,
59-GCA TTT TCT GTG CTT TCT CT-39; GAPDH sense primer, 59-TGT GAA
CGG ATT TGG CCG TA-39; and GAPDH antisense primer, 59-ACT TGC CGT
GGG TAG AGT CA-39. Real-time PCR was performed using a DNA Engine
Opticon Continuous Fluorescence Detection System (MJ Research, Waltham,
MA) for ~40 cycles.
Western blot analysis. ARC fragments were homogenized in tissue protein
extract reagent (Pierce) containing protease inhibitor cocktail (1 mmol/L
phenylmethylsulfonyl ﬂuoride, 10 mg/mL leupeptin, and 3 mmol/L aprotinin)
and 1 mmol/L sodium orthovanadate (pH 6.8). Electrophoretically separated
polypeptides were transferred onto a nitrocellulose membrane at 20 mA for
16 h. After incubation with monoclonal mouse TTF-1 (1:2,000; NeoMarkers) or
phosphorylated STAT3 (pSTAT3) (1:1,000; Cell Signaling, Beverly, MA) anti-
body for 1 h, bound antibody was detected using an enhanced chemi-
luminescence kit (Pierce).
Immunohistochemistry. Rats were anesthetized with tribromoethanol (250
mg/kg body weight; Sigma-Aldrich) and transcardially perfused with 100 mL
phosphate buffer (PB; pH 7.4), followed by 100 mL 4% paraformaldehyde. Slide-
mounted sections were prepared with a cryostat. We followed the immu-
nohistochemistry (IHC) protocol described previously (14), using primary
antibodies (anti-TTF-1 [1:1,000; NeoMarkers], anti-AgRP [1:100; Santa Cruz
Biotechnology, Santa Cruz, CA], anti-a-MSH [1:10,000; Millipore, Billerica, MA],
and anti-STAT3 [1:200; Cell Signaling]) and secondary antibodies (anti-mouse
IgG [1:500; Vector Laboratories, Burlingame, CA] for TTF-1 and anti-goat IgG
[1:500; Vector Laboratories] for AgRP, a-MSH, and STAT3). Immunoﬂuores-
cence was visualized using the TSA System (NEN Life Science, Boston, MA).
For double immunoﬂuorescence detection, after generation of the ﬁrst signals,
sections were incubated in 0.3 mol/L H2O2 for 30 min at 25°C, followed by
three 10-min washes in PB, and then developed. To determine the percentage
of cells that coexpress TTF-1 and AgRP or a-MSH in the ARC, double-labeled
cells were counted under microscopy (three sections per rat).Two observers
independently counted the cells and deﬁned colocalization as overlapping of
double immunoreactivities (TTF-1 and AgRP or a-MSH) with counter nuclear
staining (Hoeschst).
Combined IHC ﬂuorescence in situ hybridization. The ObRb (a long-form
leptin receptor) cDNA template was cloned by PCR based on sequence in-
formation deposited in the NCBI GenBank database (accession no. AF281268)
and linearized by SpeIa n dSac2 digestion to produce either sense or antisense
RNA probes, respectively. In vitro transcription of biotin-labeled ObRb cRNA
probes was performed using an RNA labeling mix (Roche, Mannheim, Germany)
and SP6 and T7 RNA polymerases (Promega). We performed ﬂuorescence in
situ hybridization (FISH) experiments according to a previous report (13) by
incubating brain sections with an antisense (or sense for negative control)
RNA probe for ObRb overnight at 63°C. The mRNA signals of ObRb were
visualized using a ﬂuorescein isothiocyanate-conjugated TSA system (NEN
Life Sciences). To colocalize ObRb mRNA with TTF-1, IHC with TTF-1 anti-
body was performed as described above.
Administrationofmaterials.Apolyethylenecannula(outerdiameter,1.05mm;
inner diameter, 0.35 mm) was stereotactically implanted into the lateral ven-
tricle(coordinates:AP=1.0mmcaudaltothebregma;V=3.6mmfromthedura
mater; L = 0.16 mm from the midline). After 1 week of recovery, test materials
were injected through the cannula.
To determine whether leptin regulates hypothalamic TTF-1 expression, rats
were fasted overnight and then injected intracerebroventricularly or in-
traperitoneally with recombinant rat leptin (4 mg i.c.v. and 2 mg/kg i.p. in-
jection; R&D Systems, Minneapolis, MN). Rats were killed 1 h after leptin
injection.
To block endogenous TTF-1 expression in the hypothalamus, a phospho-
rothioate antisense (AS) ODN (GenoTech, Daejeon, Korea) was delivered into
the lateral ventricle of adult male rats. The sequence of the AS ODN used to
disrupt TTF-1 synthesis and its scrambled (SCR) control sequence were
designed as described previously (10). ODNs were diluted to a ﬁnal concen-
tration of 0.5 nmol/mL in artiﬁcial cerebrospinal ﬂuid (10). To determine its
effect, AS ODN (2 nmol) was injected daily with an infusion syringe pump
(KDS 100; KD Scientiﬁc, Holliston, MA) up to 7 days. The animals were killed
12 h after ODN injection, and total RNA samples were prepared.
To determine whether MC3/4R mediates anorexia that was induced by
blocking hypothalamic TTF-1 synthesis, rats fasted overnight were intra-
cerebroventricularly injected daily with SHU9119 (Phoenix Pharmaceuticals,
Burlingame, CA) and AgRP (Phoenix Pharmaceuticals) 4 h after AS TTF-1 ODN
injectionfor3days.Immediatelythereafter,ratswereallowedaccesstofoodad
libitum, and their cumulative food intake was measured 6 and 24 h or 3 days
after the injection.
Statistics. Student t test was used for comparison of two groups. Differences
among more than three groups were analyzed by one-way ANOVA with
Dunnett multiple comparison post hoc tests. For analysis of daily food intake,
two-way ANOVA was used with Bonferroni post hoc tests.
RESULTS
TTF-1 regulates AgRP and POMC promoter activities.
Examination of the 59-ﬂanking region of the AgRP
and POMC genes revealed that both regions contain several
consensus core motifs for TTF-1 binding (19; Supplemen-
tary Figs. 1 and 2). Thus we performed assays for these
promoter activities affected by TTF-1. Cotransfection with
increasing concentrations of the TTF-1 expression vector
resulted in a dose-dependent increase in AgRP promoter
activity (Fig. 1A and Supplementary Fig. 3A) but a dose-
dependent decrease in POMC promoter activity (Fig. 1B
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TTF-1 on AgRP and POMC promoter activities in B35 and
AtT-20 cells, respectively, promoter assays were performed
after inhibiting TTF-1 synthesis. Blockade of endogenous
TTF-1 synthesis in these cell lines using TTF-1 shRNA (18)
decreased AgRP promoter activity and increased POMC
promoter activity (Fig. 1C).
To further conﬁrm TTF-1 function in regulation of rat
AgRP and POMC gene expression, real-time PCR analysis
of mRNA was performed using RNA samples from rat
neuroblastoma B35 cells. Cells were transfected with the
TTF-1 expression vector or TTF-1 shRNA to increase or
decrease the level of TTF-1 protein (Fig. 1D), respectively.
The AgRP mRNA level exhibited changes similar to that of
the TTF-1 protein level (Fig. 1E), whereas the change in
POMC mRNA level contrasted that of the TTF-1 protein
level (Fig. 1F), suggesting that TTF-1 activates AgRP ex-
pression but inhibits POMC expression.
TTF-1 binds in the 59-ﬂanking region of the AgRP and
POMC genes. EMSAs were performed to determine the
ability of the TTF-1 HD protein to physically interact with
putative TTF-1 binding domains in the AgRP and POMC
promoters (Fig. 2A). Double-stranded ODN probes con-
taining TTF-1 binding motifs (Supplementary Figs. 1 and 2)
were used. Of six and nine putative TTF-1 binding domains
in the AgRP and POMC promoters, four and six probes,
respectively, generated positive signals with TTF-1 HD
(Fig. 2B).
To conﬁrm whether TTF-1 physically interacts with its
binding domains in the AgRP and POMC promoters,
EMSAs were performed with nuclear proteins extracted
from rat hypothalamus. The nuclear proteins strongly
FIG. 1. Effect of TTF-1 on the transcriptional activity of the AgRP and POMC genes. Luciferase reporter constructs (pGL3) containing the 59-
ﬂanking region of the human AgRP (AGRP-pGL3) and rat POMC (POMC-pGL3) genes were cotransfected into B35 and AtT-20 cells, respectively,
with an expression vector carrying the rat TTF-1–coding region (TTF-1-pcDNA) or TTF-1 shRNA, at the ﬁnal concentration indicated. A: Trans-
activation of the AgRP promoter by different concentrations of TTF-1-pcDNA. B: Inhibitory effect of TTF-1 on the activity of the POMC promoter.
C: Inhibitory and stimulatory effect of TTF-1 shRNA on the AgRP and POMC promoter activities, respectively. D–F: TTF-1-pcDNA or TTF-1 shRNA
was transfected into B35 cells, and cells were harvested for Western blotting and real-time PCR assays 24 h after transfection. D: Western blotting
showing changes in the TTF-1 protein level after TTF-1-pcDNA or TTF-1 shRNA tranfection. E and F: Real-time PCR analysis revealing changes
in AgRP (E) and POMC mRNA (F) by overexpression and inhibition of TTF-1 synthesis. Data are represented as means 6 SEM. Each value
represents the mean of at least six repeated measurements. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control. AU, arbitrary units.
TTF-1 REGULATES MELANOCORTIN PATHWAY
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(2133) and POMC promoters (2566) (Fig. 2C). The in-
teraction between labeled probes and hypothalamic nu-
clear proteins was reduced by the addition of a 50-fold
excess of unlabeled oligonucleotide C, whereas an oligo-
nucleotide carrying a mutated core TTF-1 binding se-
quence (Cb) was ineffective. Preincubation of nuclear
proteins with TTF-1 antibody resulted in a supershifted
band from the protein-DNA complexes generated by each
of the AgRP and POMC probes, indicating that TTF-1 is
part of these complexes.
Deletion of TTF-1 binding motifs blocks the TTF-1–
induced change in AgRP and POMC promoter activities.
We next performed promoter assays with TTF-1 expression
vectors after deleting each core binding motif (59-CAAG-39 or
59-CTTG-39) from the promoters by site-directed mutagenesis.
FIG. 2. EMSAs. EMSAs were performed with double-stranded oligomer probes (5 nmol/L) containing the putative TTF-1 binding core motifs shown
in Supplementary Figs. 1 and 2 and with two different concentrations of synthetic TTF-1 HD protein (75 and 150 nmol/L). A: Representative
autoradiograms showing shifted bands generated by protein-DNA complexes. C, positive control probe. Cb, negative control probe carrying
mutations in the TTF-1 binding domain. B: Relative binding activities calculated as a percentage of TTF-1 HD binding to the positive control probe
C. ND, not detectable. C: Presence of bioactive TTF-1 in hypothalamic nuclear extracts. Hypothalamic nuclear extracts (Hypo NE) were incubated
with oligonucleotide probes indicated below the autoradiograms, in the presence (+) or absence (2) of a 50-fold excess of cold oligonucleotide C
and Cb and TTF-1 antibody (TTF-1 Ab) or preimmune serum (Pre IS). Incubation of nuclear proteins with a TTF-1 antibody before the protein-
DNA binding reaction (S, supershift) delays the migration of the protein-DNA complex. B, protein-bound DNA; F, free DNA; S, supershifted
protein-DNA complex.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 713TTF-1–dependent activation of the AgRP promoter signif-
icantly decreased with each single deletion of the binding
domains (Fig. 3A), whereas TTF-1–dependent inhibition of
POMC promoter activity was signiﬁcantly reversed by
a single deletion of each of the six TTF-1 binding motifs
(Fig. 3B). Thus the binding motifs identiﬁed by EMSAs are
required for TTF-1–dependent regulation of AgRP and
POMC promoter activities.
TTF-1 is coexpressed with AgRP and a-MSH in the
ARC. The above data strongly suggested a functional
hierarchy of TTF-1 with AgRP and a-MSH. Thus we ex-
amined the anatomical relationship of TTF-1 with AgRP
and a-MSH in the ARC. As previously reported (12,13,18),
TTF-1 immunoreactivity (green; Supplementary Fig. 4
and Fig. 4A and C) was widely distributed in the nucleus
of cells stained with Hoechst (blue; Supplementary Fig. 4)
throughout the ventromedial hypothalamic region.
Conversely, AgRP and a-MSH immunoreactivities (red;
Fig. 4A and C, respectively) were localized primarily in
cells of the ARC. Higher magniﬁcation images revealed
that the locations of AgRP and a-MSH immunoreactivities
(red; Fig. 4B and D, respectively) were closely related to
the nuclear TTF-1 signals. Most of the AgRP immuno-
reactivities were observed close to TTF-1–immunopositive
signals (Fig. 4B). a-MSH immunoreactivities appeared in
the cytoplasm surrounding nuclei containing TTF-1 immu-
noreactivities (Fig. 4D). Double staining of TTF-1 and AgRP
or a-MSH demonstrated that 80.7 6 5.78% and 94.7 6 1.86%
(n = 5 rats) of AgRP- and a-MSH–immunopositive cells were
also positive for TTF-1 immunoreactivity, respectively.
Effect of in vivo TTF-1 synthesis blockade on AgRP
and POMC expression in the ARC. To determine whether
TTF-1 is required for transcriptional regulation of the AgRP
and POMC genes in the ARC, two analyses were performed
on the ARC of rats that were administered the TTF-1 AS
ODN: histological determination of AgRP and a-MSH and
real-time PCR analysis of AgRP and POMC mRNA. The in
vivo decrease in TTF-1 availability induced opposite effects
on the immunoreactivities of AgRP (decrease) and a-MSH
(increase) in the ARC (Fig. 5A). This decrease in AgRP
immunoreactivity was very similar to that induced by the
AgRP AS ODN (Supplementary Fig. 5). Real-time PCR
analysis using RNA samples from the ARC revealed es-
sentially the same results as the histological data: the AS
ODN decreased AgRP mRNA but increased POMC mRNA
(Fig. 5B). Thus endogenously synthesized TTF-1 may play
an essential role in maintaining AgRP and a-MSH syn-
thesis in the ARC.
Effect of leptin on the hypothalamic expression of
TTF-1. Leptin is a well-known adiposity hormone that
regulates the MC signaling pathway (21,22). Thus we ex-
amined the effect of leptin on TTF-1 expression. First, to
establish an anatomical background for leptin action on
TTF-1, leptin receptor ObRb mRNA as well as STAT3 and
TTF-1 proteins were localized in the rat ARC. Combined
FISH and IHC demonstrated that TTF-1 proteins are
present in some ObRb mRNA-containing cells of the ARC
(Fig. 6A–C). The donut-shaped green ﬂuorescence revealed
cytoplasmic localization of ObRb mRNA (Fig. 6A and C),
whereas round-shaped TTF-1 immunoreactivities indicated
their nuclear localization (Fig. 6B and C). The sense RNA
probe did not generate a positive ObRb mRNA signal
(data not shown). Double IHC revealed that STAT3 and
TTF-1 proteins are coexpressed in some cells of the ARC
(Fig. 6D–F).
Leptin, administered by intracerebroventricular or in-
traperitoneal injection, signiﬁcantly decreased TTF-1 ex-
pression in the hypothalamus (Fig. 7A and B), whereas it
increased pSTAT3 (Fig. 7C). The intracerebroventricularly
injected leptin also induced a decrease in AgRP mRNA
(Fig. 7D) and an increase in POMC mRNA (Fig. 7E) in the
rat hypothalamus.
MC3/4R function in TTF-1–induced anorexia. To test
the in vivo function of TTF-1, we ﬁrst determined the effect
of the AS TTF-1 ODN on the animals’ food intake. After
daily administration of the AS ODN for 7 days, food intake
was maintained at a low level throughout the entire ob-
servation period (Fig. 8A). We next asked whether TTF-1
action on food intake is mediated by MC3/4R. To determine
this, we studied the effect of daily intracerebroventricular
administration of SHU9119, a synthetic MC3/4R antago-
nist, and AgRP, an endogenous antagonist, on TTF-1 AS
ODN-induced change in food intake of rats whose food
was deprived overnight. SHU9119 increased food intake
for 6 and 24 h and 3 days in SCR ODN-injected animals
FIG. 3. Effect of deleting core TTF-1 binding motifs on the regulation of
AgRP and POMC transcription by TTF-1. Single mutants (200 ng) with
core TTF-1 binding motifs deleted from the AgRP (A) and POMC (B)
promoters were cotransfected with 500 ng of the TTF-1 expression
vector TTF-1-pcDNA. The positions of the deleted binding sites are
indicated. Data are represented as means 6 SEM of 12 wells per con-
struct. ###P < 0.001 vs. the wild-type promoter transfected with con-
trol pcDNA; *P < 0.05, **P < 0.01, and ***P < 0.001 vs. change in the
wild-type promoter activity induced by TTF-1-pcDNA. AU, arbitrary
units.
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was administered to AS ODN-injected animals, it partially
antagonized the anorexic effect of the AS ODN (Fig. 8B–D).
Thus the decrease in food intake induced by the TTF-1 AS
ODN may, at least partially, occur through MC3/4R. AgRP
did not alter the food intake of SCR ODN-injected rats
(Fig. 8E and F). Conversely, it dramatically recovered
anorexia induced by the AS ODN, and moreover it in-
duced a relatively greater attenuation of the anorexia
caused by AS TTF-1 ODN than the SHU9119. Together,
these data suggest that endogenously synthesized TTF-1
regulates the levels of a-MSH (decrease) and AgRP (in-
crease) that converge and act on MC3/4R to regulate food
intake.
FIG. 4. Detection of TTF-1 immunoreactive materials in AgRP- and a-MSH–immunopositive cells in the rat hypothalamic ARC. Double immuno-
histochemistry was performed on brain sections derived from normally fed 2-month-old male rats. TTF-1 immunoreactivities (green) showed
a relatively wide distribution in the section, whereas immunopositive AgRP (red; A and B)a n da-MSH (red; C and D) were present only in the ARC.
A: TTF-1 immunoreactivity near the AgRP immunoreactivity in the ARC as well as in the ependymal/subependymal cells lining the third ventricle
(arrowhead) and astrocytes in the median eminence (arrow). B: A higher magniﬁcation image showing colocalization of the immunoreactivity of
TTF-1 and AgRP in the ARC. AgRP immunoreactivity appeared close to TTF-1–positive nuclei with some overlapping (arrows). C: Presence of TTF-
1 immunoreactivity in a-MSH–immunopositive cells in the ARC. D: A higher magniﬁcation image highlighting colocalization of both TTF-1 and
a-MSH immunoreactivities in some cells (arrows). Scale bar = 50 mm. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
FIG. 5. Effect of TTF-1 synthesis blockade by AS TTF-1 ODN on AgRP and a-MSH synthesis in the ARC. The TTF-1 AS ODN or SCR ODN was
injected into the lateral ventricle of 2-month-old male rats. Twelve hours after the ODN injection, brains were ﬁxed by transcardiac perfusion for
IHC or were sliced for excising the ARC using a micropunch. Hypothalamic expression of TTF-1, AgRP, and a-MSH (or POMC) was determined by
IHC and real-time PCR. A: Representative microphotographs showing a decrease in immunoreactive signals of TTF-1 and AgRP and increased
a-MSH immunoreactivity in the ARC caused by the AS TTF-1 ODN. B: Data from real-time PCR analysis showing decreased AgRP mRNA and
increased POMC mRNA resulting from decreased TTF-1 content in the ARC, which is induced by intracerebroventricular administration of the
TTF-1 AS ODN (AS) compared with the SCR ODN (SCR). Data are represented as means 6 SEM (n = 6). *P < 0.05 and **P < 0.01 vs. SCR. AU,
arbitrary units. (A high-quality color representation of this ﬁgure is available in the online issue.)
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Our results demonstrate an important role for TTF-1 in the
control of food intake via regulation of the synthesis of
AgRP and a-MSH in the ARC.
Based on well-conserved TTF-1 binding core motifs pre-
viously found in the target gene promoters (8,10,11,13,19),
we identiﬁed six and nine putative TTF-1 binding motifs in
the 59-ﬂanking regions of the AgRP and POMC genes, re-
spectively. EMSAs revealed that TTF-1 interacts with four
and six sites, respectively, from the presumptive binding
domains in the AgRP and POMC promoters. Promoter
assays, using mutant promoters bearing a single deletion of
each of the four (AgRP) and six (POMC) core binding
motifs, revealed a signiﬁcantly reduced TTF-1 dependency
in the activities of these promoters, suggesting that TTF-1
directly regulates AgRP and POMC transcription by binding
to recognition sites in the promoters of these genes.
Overexpression of TTF-1 increased AgRP promoter
activity and mRNA, whereas it decreased POMC pro-
moter activity and mRNA. Transfection with shRNA
resulted in decreased availability of TTF-1, producing
results contrary with those observed with TTF-1 over-
expression: a decrease and an increase in AgRP and
POMC promoter activities and mRNAs, respectively. Thus
TTF-1 transcriptionally regulates the endogenous agonist
(a-MSH) and antagonist (AgRP) of the MC pathway. The
opposing actions of TTF-1 in regulating closely related
target genes have been reported for genes encoding
growth hormone (inhibited by TTF-1) and prolactin
(activated) in anterior pituitary cell lines (18) and lutei-
nizing hormone-releasing hormone (activated) and pre-
proenkephalin (inhibited) in the rat hypothalamus (8).
In vivo inhibition of TTF-1 synthesis in the rat ARC
exerted the same effect as that observed in the in vitro cell
studies: it decreased AgRP mRNA and protein levels and
increased POMC mRNA and a-MSH content in the ARC. It
was also associated with decreased food intake, which was
reversed by MC3/4R antagonists (SHU9119 and AgRP). To
inhibit TTF-1 synthesis in vivo, we used an AS TTF-1 ODN
(10,11,13,14). Although intracerebroventricular administra-
tion of the AS ODN may affect areas adjacent to the ven-
tricular region, we demonstrated, using IHC, that injection
of the AS ODN into the lateral ventricle led to a marked
decrease in TTF-1 availability in the ARC. We conﬁrmed this
by immunoblot analysis of TTF-1 in the ARC, which
revealed a decreased TTF-1 signal induced by the AS ODN.
TTF-1 is expressed in the embryonic diencephalon and
lung (24). In brains of mice carrying a TTF-1–null mutation,
extensive abnormalities are found in the preoptic and hy-
pothalamic areas, and the ARC is absent (25), suggesting
that TTF-1 is important for the formation of these areas.
TTF-1 is expressed in discrete regions of the postnatal rat
brain and can regulate the synthesis of several neuro-
peptides and proteins in adult animals (8–13). Although
previous studies have reported expression of TTF-1 mRNA
and/or protein in the ARC (8,9,14), this study is the ﬁrst to
directly show histochemically that TTF-1 functionally asso-
ciates with the leptin receptor and AgRP and a-MSH in the
ARC, the center of neural control of energy balance. Nota-
bly, cells in the ARC that are positive for AgRP and POMC
coexpress TTF-1, providing anatomical evidence for the
functional hierarchy between them.
The regional domain of TTF-1 expression in the hypo-
thalamus is broader than that of AgRP and POMC ex-
pression. Moreover, only some TTF-1–positive cells in the
ARC were also positive for AgRP or POMC, but most cells
expressing either of the two neuropeptides were also im-
munoreactive to TTF-1. This ﬁnding is consistent with
previous studies showing multiple functions of TTF-1 in
the transregulation of several other target genes in the
hypothalamus (8,12,14).
The hypothalamic MC signaling pathway is important in
the regulation of energy homeostasis through integration
of peripheral hormonal signals such as leptin, cholecys-
tokinin, and ghrelin (26). We showed that leptin, which is
FIG. 6. Identiﬁcation of TTF-1 immunoreactivity in cells expressing ObRb and STAT3 in the rat ARC. Combined FISH and IHC were performed to
determine ObRb mRNA and TTF-1 protein (A–C), and double IHC was performed for colocalization of STAT3 and TTF-1 (D–F). A: Green ﬂuo-
rescence signals representing ObRb mRNA in the cytoplasm of the ARC cells. B: Red signals revealing TTF-1 immunoreactivity in the nucleus of
cells in the ARC and some ependymal cells of the third ventricle. C: Merged image of A and B showing some cells double positive for ObRb mRNA
and TTF-1. D and E: STAT3 (green; D) and TTF-1 (red; E) immunoreactivities in cells of the rat ARC and ependymal cells of the third ventricle.
F: Merged image of D and E showing some cells with colocalization of TTF-1 and STAT3 proteins. Scale bar = 50 mm. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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ing a-MSH and inhibiting AgRP (22), decreased hypotha-
lamic TTF-1 expression. This was further supported by
histochemical data demonstrating that expression domains
of ObRb and STAT3 overlap with that of TTF-1 in some
ARC cells. Thus TTF-1 may mediate regulatory inputs such
as leptin to control feeding behavior.
MC3/4R is found in brain areas involved in the control
of energy balance, including the ARC, and the para-
ventricular, lateral, and ventromedial nuclei of the hypo-
thalamus (27). Central administration of MC3/4R agonists
a-MSH and melanotan-II (MTII) reduced food intake and
body weight (28). Conversely, treatment with MC3/4R
antagonists AgRP and SHU9119 resulted in hyperphagia
and increased body weight (28–30). Because hypothalamic
TTF-1 simultaneously regulates AgRP and a-MSH synthe-
sis oppositely, TTF-1 in the ARC may exert its orexigenic
effect through the MC3/4R signaling pathway. This was
supported by experiments showing that SHU9119 and
AgRP diminished anorexia induced by in vivo TTF-1 syn-
thesis blockade in the ARC. However, the sustained an-
orexic effect of TTF-1 AS ODN suggests that TTF-1 may
act on feeding behavior partly through pathways other
than MC3/4R, because exogenous infusion of a-MSH or
MTII did not cause sustained reduction in food intake
(31–33). Moreover, anorexia induced by AS TTF-1 ODN
was not completely abolished by blockade of MC3/4R with
SHU9119 or AgRP. Therefore, TTF-1 may also contribute
to the regulation of appetite through other pathway(s) in
addition to the MC pathway. For example, our previous
studies have shown that TTF-1 regulates the transcription
of genes encoding pituitary adenylate cyclase-activating
polypeptide (10), proenkephalin (8), and more importantly
NPY (14), which are known to be involved in the regula-
tion of food intake.
Although this study demonstrated TTF-1 action on
food intake, how upstream signaling inputs such as leptin
alter TTF-1 expression, and what normal physiological
changes require TTF-1 for feeding regulation are largely
unknown. Although our previous ﬁnding showed that fast-
ing signiﬁcantly induced an increase in TTF-1 expression
(14), further studies are required to answer these questions.
In summary, this study revealed that TTF-1 regulates
AgRP and POMC expression in the hypothalamus under
a signaling input from leptin, thus affecting food intake.
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